{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:14:40Z","timestamp":1792034080857,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To delineate the genomic and cellular features of CCNE1 amplification across gynecologic cancer types using large-scale multi-omics data and assess its relevance for patient stratification and therapeutic targeting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed genomic and transcriptomic data from 12,845 patients with gynecological cancers curated from the cBioPortal database, including ovarian, endometrial, and cervical carcinomas. CCNE1 amplification rates, cooccurring genomic alterations, and pathway enrichment were evaluated. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomic data from cervical, endometrial, and ovarian tumors were used to investigate CCNE1 expression patterns, cell type specificity, and microenvironmental interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CCNE1 amplification was detected in 8.40% of all patients, with the highest rates in patients with ovarian cancer (8.01%) and endometrial cancer (5.06%). Among the ovarian subtypes, carcinosarcoma showed the highest amplification frequency (12.46%), followed by high-grade serous carcinoma (9.84%). Amplified tumors are frequently co-altered by TP53, PIK3CA, and PI3K-AKT pathway genes. Single-cell analyses revealed that CCNE1 expression was largely confined to epithelial cells and was associated with proliferative and structural remodeling pathways, with limited immune engagement across tumor types. Spatial transcriptomics confirmed the localization of CCNE1 in epithelial-rich regions and its correlation with adhesion- and motility-related genes in clear cell and high-grade serous ovarian carcinomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CCNE1 amplification is enriched in aggressive histologic subtypes of gynecological cancers and is linked to epithelial-specific expression and immune exclusion. These findings indicate that CCNE1 represents a potential molecular marker for tumor aggressiveness, warranting further investigation in the context of patient stratification and therapeutic targeting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12672-025-04032-7","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:04:56Z","timestamp":1764720296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multiomic analysis of CCNE1 amplification associated molecular and immune features in gynecological cancers"],"prefix":"10.1007","volume":"16","author":[{"given":"Linlin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanguang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"3","key":"4032_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"4032_CR2","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41588-018-0179-8","volume":"50","author":"G Macintyre","year":"2018","unstructured":"Macintyre G, et al. Copy number signatures and mutational processes in ovarian carcinoma. Nat Genet. 2018;50(9):1262\u201370.","journal-title":"Nat Genet"},{"issue":"9","key":"4032_CR3","doi-asserted-by":"publisher","first-page":"102108","DOI":"10.1016\/j.labinv.2024.102108","volume":"104","author":"O Reich","year":"2024","unstructured":"Reich O, Regauer S, Gutierrez AL, Kashofer K. Copy number profiling implicates thin High-Grade squamous intraepithelial lesions as a true precursor of cervical human Papillomavirus-Induced squamous cell cancer. Lab Invest. 2024;104(9):102108.","journal-title":"Lab Invest"},{"issue":"7916","key":"4032_CR4","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41586-022-04738-6","volume":"606","author":"CD Steele","year":"2022","unstructured":"Steele CD, et al. Signatures of copy number alterations in human cancer. Nature. 2022;606(7916):984\u201391.","journal-title":"Nature"},{"issue":"9","key":"4032_CR5","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.22.02267","volume":"41","author":"G Au-Yeung","year":"2023","unstructured":"Au-Yeung G, Mileshkin L, Bowtell DDL. CCNE1 amplification as a therapeutic target. J Clin Oncol. 2023;41(9):1770\u20133.","journal-title":"J Clin Oncol"},{"issue":"7353","key":"4032_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research N","year":"2011","unstructured":"Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609\u201315.","journal-title":"Nature"},{"issue":"3","key":"4032_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","volume":"31","author":"AD Cherniack","year":"2017","unstructured":"Cherniack AD, et al. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell. 2017;31(3):411\u201323.","journal-title":"Cancer Cell"},{"issue":"8","key":"4032_CR8","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1073\/pnas.1222577110","volume":"110","author":"S Zhao","year":"2013","unstructured":"Zhao S, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A. 2013;110(8):2916\u201321.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"4032_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/modpathol.2016.160","volume":"30","author":"A Ayhan","year":"2017","unstructured":"Ayhan A, et al. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis. Mod Pathol. 2017;30(2):297\u2013303.","journal-title":"Mod Pathol"},{"issue":"32","key":"4032_CR10","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1038\/onc.2012.387","volume":"32","author":"RM Jones","year":"2013","unstructured":"Jones RM, et al. Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress. Oncogene. 2013;32(32):3744\u201353.","journal-title":"Oncogene"},{"issue":"1","key":"4032_CR11","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1038\/s41467-025-58183-w","volume":"16","author":"H Xu","year":"2025","unstructured":"Xu H, et al. Targeting CCNE1 amplified ovarian and endometrial cancers by combined Inhibition of PKMYT1 and ATR. Nat Commun. 2025;16(1):3112.","journal-title":"Nat Commun"},{"issue":"7","key":"4032_CR12","doi-asserted-by":"publisher","first-page":"109978","DOI":"10.1016\/j.isci.2024.109978","volume":"27","author":"H Xu","year":"2024","unstructured":"Xu H, et al. CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience. 2024;27(7):109978.","journal-title":"iScience"},{"issue":"9","key":"4032_CR13","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1200\/JCO.22.00830","volume":"41","author":"S Fu","year":"2023","unstructured":"Fu S, et al. Multicenter phase II trial of the WEE1 inhibitor Adavosertib in refractory solid tumors harboring CCNE1 amplification. J Clin Oncol. 2023;41(9):1725\u201334.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4032_CR14","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1158\/1535-7163.MCT-21-0873","volume":"21","author":"S Bai","year":"2022","unstructured":"Bai S, et al. Targeting therapeutic resistance and multinucleate giant cells in CCNE1-Amplified HR-Proficient ovarian cancer. Mol Cancer Ther. 2022;21(9):1473\u201384.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"4032_CR15","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1172\/JCI122622","volume":"129","author":"AB Bukhari","year":"2019","unstructured":"Bukhari AB, Lewis CW, Pearce JJ, Luong D, Chan GK, Gamper AM. Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis. J Clin Invest. 2019;129(3):1329\u201344.","journal-title":"J Clin Invest"},{"issue":"7907","key":"4032_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41586-022-04638-9","volume":"604","author":"D Gallo","year":"2022","unstructured":"Gallo D, et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase Inhibition. Nature. 2022;604(7907):749\u201356.","journal-title":"Nature"},{"issue":"7","key":"4032_CR17","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1158\/0008-5472.CAN-24-2360","volume":"85","author":"NC House","year":"2025","unstructured":"House NC, et al. Profiling the activity of the potent and highly selective CDK2 inhibitor BLU-222 reveals determinants of response in CCNE1-Aberrant ovarian and endometrial tumors. Cancer Res. 2025;85(7):1297\u2013309.","journal-title":"Cancer Res"},{"key":"4032_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00011","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty D, et al. OncoKB: A precision oncology knowledge base. JCO Precis Oncol. 2017. https:\/\/doi.org\/10.1200\/PO.17.00011.","journal-title":"JCO Precis Oncol"},{"key":"4032_CR19","doi-asserted-by":"publisher","first-page":"200299","DOI":"10.1016\/j.tvr.2024.200299","volume":"19","author":"E Robinson","year":"2025","unstructured":"Robinson E, et al. Analysis of the progression of cervical cancer in a low-and-middle-income country: from pre-malignancy to invasive disease. Tumour Virus Res. 2025;19:200299.","journal-title":"Tumour Virus Res"},{"key":"4032_CR20","doi-asserted-by":"publisher","first-page":"216408","DOI":"10.1016\/j.canlet.2023.216408","volume":"576","author":"S Yue","year":"2023","unstructured":"Yue S, Wang Q, Zhang J, Hu Q, Liu C. Understanding cervical cancer at single-cell resolution. Cancer Lett. 2023;576:216408.","journal-title":"Cancer Lett"},{"issue":"1","key":"4032_CR21","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s42003-022-04142-w","volume":"5","author":"C Li","year":"2022","unstructured":"Li C, et al. Single-cell transcriptomics reveals cellular heterogeneity and molecular stratification of cervical cancer. Commun Biol. 2022;5(1):1208.","journal-title":"Commun Biol"},{"key":"4032_CR22","doi-asserted-by":"publisher","first-page":"897366","DOI":"10.3389\/fimmu.2022.897366","volume":"13","author":"C Li","year":"2022","unstructured":"Li C, Hua K. Dissecting the Single-Cell transcriptome network of immune environment underlying cervical premalignant Lesion, cervical cancer and metastatic lymph nodes. Front Immunol. 2022;13:897366.","journal-title":"Front Immunol"},{"issue":"7447","key":"4032_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"Cancer Genome Atlas Research N","year":"2013","unstructured":"Cancer Genome Atlas Research N. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67\u201373.","journal-title":"Nature"},{"issue":"7","key":"4032_CR24","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","volume":"35","author":"DS Ross","year":"2022","unstructured":"Ross DS, et al. Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas. Mod Pathol. 2022;35(7):962\u201371.","journal-title":"Mod Pathol"},{"issue":"9","key":"4032_CR25","doi-asserted-by":"publisher","first-page":"14794","DOI":"10.18632\/oncotarget.11605","volume":"8","author":"A Noske","year":"2017","unstructured":"Noske A, et al. Detection of CCNE1\/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer. Oncotarget. 2017;8(9):14794\u2013805.","journal-title":"Oncotarget"},{"issue":"7","key":"4032_CR26","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/modpathol.2013.209","volume":"27","author":"E Kuhn","year":"2014","unstructured":"Kuhn E, Bahadirli-Talbott A, Shih Ie M. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. Mod Pathol. 2014;27(7):1014\u20139.","journal-title":"Mod Pathol"},{"issue":"7","key":"4032_CR27","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1136\/ijgc-2024-005295","volume":"34","author":"E Dugo","year":"2024","unstructured":"Dugo E, Piva F, Giulietti M, Giannella L, Ciavattini A. Copy number variations in endometrial cancer: from biological significance to clinical utility. Int J Gynecol Cancer. 2024;34(7):1089\u201397.","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"4032_CR28","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41568-023-00591-5","volume":"23","author":"Q Zeng","year":"2023","unstructured":"Zeng Q, et al. Understanding tumour endothelial cell heterogeneity and function from single-cell omics. Nat Rev Cancer. 2023;23(8):544\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"4032_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41419-024-06960-8","volume":"15","author":"F Ren","year":"2024","unstructured":"Ren F, et al. Single-cell transcriptome profiles the heterogeneity of tumor cells and microenvironments for different pathological endometrial cancer and identifies specific sensitive drugs. Cell Death Dis. 2024;15(8):571.","journal-title":"Cell Death Dis"},{"issue":"7553","key":"4032_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"AM Patch","year":"2015","unstructured":"Patch AM, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489\u201394.","journal-title":"Nature"},{"issue":"35","key":"4032_CR31","doi-asserted-by":"publisher","first-page":"37663","DOI":"10.18632\/oncotarget.5438","volume":"6","author":"SM Hunter","year":"2015","unstructured":"Hunter SM, et al. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget. 2015;6(35):37663\u201377.","journal-title":"Oncotarget"},{"issue":"12","key":"4032_CR32","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41588-022-01230-9","volume":"54","author":"DW Garsed","year":"2022","unstructured":"Garsed DW, et al. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nat Genet. 2022;54(12):1853\u201364.","journal-title":"Nat Genet"},{"issue":"16","key":"4032_CR33","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","volume":"363","author":"KC Wiegand","year":"2010","unstructured":"Wiegand KC, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532\u201343.","journal-title":"N Engl J Med"},{"issue":"4","key":"4032_CR34","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1158\/1078-0432.CCR-08-1564","volume":"15","author":"D Etemadmoghadam","year":"2009","unstructured":"Etemadmoghadam D, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res. 2009;15(4):1417\u201327.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"4032_CR35","first-page":"13392","volume":"16","author":"Y Ouyang","year":"2024","unstructured":"Ouyang Y, Wu Z, Aili D, Yang C, Zhang H, Wu T. Pan-cancer analysis identifies the oncogenic role of CCNE1 in human cancers. Aging. 2024;16(21):13392\u2013408.","journal-title":"Aging"},{"issue":"4","key":"4032_CR36","doi-asserted-by":"publisher","first-page":"e1119356","DOI":"10.1080\/2162402X.2015.1119356","volume":"5","author":"A Serrels","year":"2016","unstructured":"Serrels A, Frame MC. FAK goes nuclear to control antitumor immunity-a new target in cancer immuno-therapy. Oncoimmunology. 2016;5(4):e1119356.","journal-title":"Oncoimmunology"},{"issue":"1","key":"4032_CR37","doi-asserted-by":"publisher","first-page":"e1376155","DOI":"10.1080\/2162402X.2017.1376155","volume":"7","author":"S Kumar","year":"2017","unstructured":"Kumar S, et al. Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer. Oncoimmunology. 2017;7(1):e1376155.","journal-title":"Oncoimmunology"},{"key":"4032_CR38","doi-asserted-by":"publisher","first-page":"657219","DOI":"10.3389\/fcell.2021.657219","volume":"9","author":"C Yang","year":"2021","unstructured":"Yang C, et al. Transcriptomic analysis identified ARHGAP family as a novel biomarker associated with Tumor-Promoting immune infiltration and Nanomechanical characteristics in bladder cancer. Front Cell Dev Biol. 2021;9:657219.","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"4032_CR39","doi-asserted-by":"publisher","first-page":"e2304342","DOI":"10.1002\/advs.202304342","volume":"11","author":"N Wang","year":"2024","unstructured":"Wang N, et al. Protein kinase STK24 promotes tumor immune evasion via the AKT-PD-L1 axis. Adv Sci (Weinh). 2024;11(12):e2304342.","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"4032_CR40","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/2159-8290.CD-23-0954","volume":"14","author":"C Dietrich","year":"2024","unstructured":"Dietrich C, et al. INX-315, a selective CDK2 Inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discov. 2024;14(3):446\u201367.","journal-title":"Cancer Discov"},{"issue":"1","key":"4032_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/ijgc-2021-003144","volume":"32","author":"J Liu","year":"2022","unstructured":"Liu J, Oza AM, Colombo N, Oaknin A. ADAGIO: a phase IIb international study of the Wee1 inhibitor Adavosertib in women with recurrent or persistent uterine serous carcinoma. Int J Gynecol Cancer. 2022;32(1):89\u201392.","journal-title":"Int J Gynecol Cancer"},{"key":"4032_CR42","doi-asserted-by":"crossref","unstructured":"Garrido-Castro AC et al. Phase I study of ribociclib (CDK4\/6 inhibitor) with Spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer. J Immunother Cancer. 2025;13(2).","DOI":"10.1136\/jitc-2024-010430"},{"issue":"2","key":"4032_CR43","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1158\/1078-0432.CCR-23-0433","volume":"30","author":"N Nayyar","year":"2024","unstructured":"Nayyar N, et al. CDK4\/6 Inhibition sensitizes intracranial tumors to PD-1 Blockade in preclinical models of brain metastasis. Clin Cancer Res. 2024;30(2):420\u201335.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4032_CR44","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","volume":"22","author":"DA Schaer","year":"2018","unstructured":"Schaer DA, et al. The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint Blockade. Cell Rep. 2018;22(11):2978\u201394.","journal-title":"Cell Rep"},{"issue":"1","key":"4032_CR45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","volume":"13","author":"M Jiang","year":"2020","unstructured":"Jiang M, et al. cGAS-STING, an important pathway in cancer immunotherapy. J Hematol Oncol. 2020;13(1):81.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"4032_CR46","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41416-018-0188-5","volume":"119","author":"A Ghaffari","year":"2018","unstructured":"Ghaffari A, et al. STING agonist therapy in combination with PD-1 immune checkpoint Blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. Br J Cancer. 2018;119(4):440\u20139.","journal-title":"Br J Cancer"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04032-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04032-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04032-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:55:52Z","timestamp":1781621752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04032-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4032"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04032-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used publicly available, de-identified datasets and did not involve new human or animal experiments. Therefore, ethical approval and informed consent were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study did not include any individual patient data. Therefore, consent for publication was not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2225"}}